Apolipoprotein A5 gene variants and the risk ofcoronary heart disease: A case-control study and meta-analysis

Molecular Medicine Reports

Volumn 8, Issue 4, 2013, Pages 1175-1182

  Zhou, Jianqing ^a   Xu, Limin ^a   Huang, Rong Stephanie ^b   Huang, Yi ^a   Le, Yanping ^a   Jiang, Danjie ^a   Yang, Xi ^a   Xu, Weifeng ^a   Huang, Xiaoyan ^a   Dong, Changzheng ^a   Ye, Meng ^a   Lian, Jiangfang ^a   Duan, Shiwei ^a  

^a NINGBO UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

1131T>C; 553G>T; APOA5; Coronary heart disease; S19W; SNP

Indexed keywords

APOLIPOPROTEIN A5; GENOMIC DNA; APOA5 PROTEIN, HUMAN; APOLIPOPROTEIN A;

ANGIOCARDIOGRAPHY; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; CORONARY RISK; CORRELATION ANALYSIS; DISEASE SEVERITY; DOMINANT INHERITANCE; ETHNIC DIFFERENCE; FEMALE; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; BIOLOGICAL MODEL; CORONARY ARTERY DISEASE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; RISK FACTOR; STATISTICAL MODEL;

APOLIPOPROTEINS A; CASE-CONTROL STUDIES; CORONARY DISEASE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84883437988     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1642     Document Type: Article

References (44)

1. Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C and Sacks FM: Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol 106: 757-763, 2010.
2. Maász A, Kisfali P, Horvatovich K, et al: Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. Pathol Oncol Res 13: 243-247, 2007.
3. Evans D, Aberle J and Beil FU: Resequencing the apolipoprotein A5 (APOA5) gene in patients with various forms of hypertriglyceridemia. Atherosclerosis 219: 715-720, 2011.
4. Peden JF and Farrall M: Thirty-five common variants for coronary artery disease: the fruits of much collaborative labour. Hum Mol Genet 20: R198-R205, 2011.
5. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM and Rubin EM: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294: 169-173, 2001.
6. Martinelli N, Trabetti E, Bassi A, Girelli D, Friso S, Pizzolo F, Sandri M, Malerba G, Pignatti PF, Corrocher R and Olivieri O: The -1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study. Atherosclerosis 191: 409-417, 2007.
7. Szalai C, Keszei M, Duba J, Prohászka Z, Kozma GT, Császár A, Balogh S, Almássy Z, Fust G and Czinner A: Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis 173: 109-114, 2004.
8. Liu H, Zhang S, Lin J, et al: Association between DNA variant sites in the apolipoprotein A5 gene and coronary heart disease in Chinese. Metabolism 54: 568-572, 2005.
9. Sarwar N, Sandhu MS, Ricketts SL, et al: Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375: 1634-1639, 2010.
10. Yu Y, Xue L and Zhao CY: Study on polymorphism in the apolipoprotein A5 gene in patients with premature coronary heart disease. Beijing Da Xue Xue Bao 39: 576-580, 2007 (In Chinese).
11. Li X, Yao C, Song M, Ma J, Ning H and Hu B: The relationship between the polymorphism of apolipoprotein A5 gene 56C>G and the level of serum triglyceride. Ningxia Yi Xue Za Zhi 9: 643-645, 2006 (In Chinese).
12. Lai CQ, Tai ES, Tan CE, Cutter J, Chew SK, Zhu YP, Adiconis X and Ordovas JM: The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res 44: 2365-2373, 2003.
13. Kao JT, Wen HC, Chien KL, Hsu HC and Lin SW: A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 12: 2533-2539, 2003.
14. Tang Y, Sun P, Guo D, Ferro A, Ji Y, Chen Q and Fan L: A genetic variant c.553G>T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels in a Chinese population. Atherosclerosis 185: 433-437, 2006.
15. Prochaska CL, Picheth G, Anghebem-Oliveira MI, Costantini CO, de Souza EM, Pedrosa FO and Scartezini M: The polymorphisms -1131T>C and the S19W of the APOA5 gene are not associated with coronary artery disease in a Brazilian population. Clin Chem Lab Med 48: 419-422, 2010.
16. Maász A, Kisfali P, Szolnoki Z, Hadarits F and Melegh B: Apolipoprotein A5 gene C56G variant confers risk for the development of large-vessel associated ischemic stroke. J Neurol 255: 649-654, 2008.
17. No authors listed: Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 59: 607-609, 1979.
18. Nikus KC: Chapter 4: Coranory angiography. In: Multimodal Imaging: Principles and Clinical Applications: Section I: Current methods and their applications for cardiovascular multimodal imaging. Pahlm O and Wagner GS (eds). McGraw-Hill Medical, New York, NY, p75, 2011.
19. Higgs ZC, Macafee DA, Braithwaite BD and Maxwell-Armstrong CA: The Seldinger technique: 50 years on. Lancet 366: 1407-1409, 2005.
20. Gabriel S, Ziaugra L and Tabbaa D: SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet (Suppl 60): 2.12.1-2.12.18, 2009.
21. Excoffier L and Lischer HE: Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour 10: 564-567, 2010.
22. Sham PC and Curtis D: Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 59 (Pt 1): 97-105, 1995.
23. Dupont WD and Plummer WD Jr: Power and sample size calculations. A review and computer program. Control Clin Trials 11: 116-128, 1990.
24. Aberle J, Evans D, Beil FU and Seedorf U: A polymorphism in the apolipoprotein A5 gene is associated with weight loss after short-term diet. Clin Genet 68: 152-154, 2005.
25. Liu HK, Wang CT, Zhang SZ, et al: Association of APOA5 gene single nucleotide polymorphism with levels of lipids and coronary heart disease in Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 21: 335-338, 2004 (In Chinese).
26. Yuan S, Ma YT, Xie X, Yang YN, Fu ZY, Ma X, Li XM, Xiang Y, Liu F and Chen BD: Association of apolipoprotein A5 gene polymorphism with coronary heart disease in Uygur population of Xinjiang. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28: 73-77, 2011 (In Chinese).
27. Hubacek JA, Wang WW, Skodová Z, Adámková V, Vráblík M, Horínek A, Stulc T, Ceska R and Talmud PJ: APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. Clin Chem Lab Med 46: 773-777, 2008.
28. Eichenbaum-Voline S, Olivier M, Jones EL, et al: Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 24: 167-174, 2004.
29. Yuan S, Ma YT, Xie X, Yang YN, Fu ZY, Ma X, Li XM, Liu F and Chen BD: Association between apolipoprotein A5 gene polymorphism and coronary heart disease in the Han population from Xinjiang. Zhonghua Liu Xing Bing Xue Za Zhi 32: 51-54, 2011 (In Chinese).
30. Song KH, Yu SG, Cha S and Kim JY: Association of the Apolipoprotein A5 gene -1131T>C polymorphism with serum lipids in Korean subjects: impact of Sasang constitution. Evid Based Complement Alternat Med 2012: 598394, 2012.
31. Ramakrishnan L, Sachdev HS, Sharma M, et al: Relationship of APOA5, PPARγ and HL gene variants with serial changes in childhood body mass index and coronary artery disease risk factors in young adulthood. Lipids Health Dis 10: 68, 2011.
32. Yan SK, Cheng XQ, Song YH, Xiao XH, Bi N and Chen BS: Apolipoprotein A5 gene polymorphism -1131T→C: association with plasma lipids and type 2 diabetes mellitus with coronary heart disease in Chinese. Clin Chem Lab Med 43: 607-612, 2005.
33. Havasi V, Szolnoki Z, Talián G, et al: Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J Mol Neurosci 29: 177-183, 2006.
34. Maasz A, Kisfali P, Jaromi L, Horvatovich K, Szolnoki Z, Csongei V, Safrany E, Sipeky C, Hadarits F and Melegh B: Apolipoprotein A5 gene IVS3+G476A allelic variant confers susceptibility for development of ischemic stroke. Circ J 72: 1065-1070, 2008.
35. Jang Y, Paik JK, Hyun YJ, Chae JS, Kim JY, Choi JR, Lee SH, Shin DJ, Ordovas JM and Lee JH: The apolipoprotein A5 -1131T>C promoter polymorphism in Koreans: association with plasma APOA5 and serum triglyceride concentrations, LDL particle size and coronary artery disease. Clin Chim Acta 402: 83-87, 2009.
36. Ruiz-Narváez EA, Yang Y, Nakanishi Y, Kirchdorfer J and Campos H: APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica. J Lipid Res 46: 2605-2613, 2005.
37. Hubacek JA, Skodová Z, Adámková V, Lánská V and Poledne R: The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction. Clin Genet 65: 126-130, 2004.
38. Dallongeville J, Cottel D, Montaye M, Codron V, Amouyel P and Helbecque N: Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men. Int J Cardiol 106: 152-156, 2006.
39. Dorfmeister B, Zeng WW, Dichlberger A, et al: Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler Thromb Vasc Biol 28: 1866-1871, 2008.
40. Johansen CT, Kathiresan S and Hegele RA: Genetic determinants of plasma triglycerides. J Lipid Res 52: 189-206, 2011.
41. Lim S, Park YM, Sakuma I and Koh KK: How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol. Int J Cardiol 166: 8-14, 2013.
42. Hokanson JE and Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3: 213-219, 1996.
43. Merkel M and Heeren J: Give me A5 for lipoprotein hydrolysis! J Clin Invest 115: 2694-2696, 2005.
44. Li G, Wang JY, Yan S, Zhang LJ, Xue H, Zeng WW, Wu G and Chen BS: The relationship between the polymorphism of apolipoprotein A5 gene 56C?G and the levels of serum triglyceride. Zhonggua Dong Mai Ying Hua Za Zhi 5: 574-576, 2004 (In Chinese).